Liquid biopsy: an essential tool for metastatic breast cancer's follow-up.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-09-15 DOI:10.1080/14622416.2025.2558500

Joe Chalhoub, Mélissa El Hajj, Tia Kreidy, Moustapha Rteil, Roland Eid, Hampig Raphael Kourie

{"title":"Liquid biopsy: an essential tool for metastatic breast cancer's follow-up.","authors":"Joe Chalhoub, Mélissa El Hajj, Tia Kreidy, Moustapha Rteil, Roland Eid, Hampig Raphael Kourie","doi":"10.1080/14622416.2025.2558500","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is the most common malignancy in women worldwide. While personalized treatment options are obstructed by the limitations of conventional biopsy follow-up, the liquid biopsy could detect the tumor's characteristics in order to reach a more targeted therapy for metastatic breast cancer patients. The aim of this article is to review the characteristics of the liquid biopsy in the follow-up of metastatic breast cancer patients. A comprehensive literature search was conducted using the PubMed literature to retrieve topic-related articles using keywords 'metastatic breast cancer,' 'liquid biopsy' and 'follow up.' A descriptive analysis was undertaken, and 29 original articles were retained. The study of blood biomarkers is being used in the monitoring and follow-up of metastatic breast cancer. It is used to determine the survival rate based on different biomarkers and monitor the response to treatment through the status of the tumor. This review describes the latest findings on breast cancer's circulating tumor cells, circulating cell-free DNA, circulating tumor DNA, proteomes, and extracellular vesicles (exosomes) in the plasma. Our literature review revealed that the liquid biopsy is capable of detecting breast cancer biomarkers in order to monitor breast cancer patients, improve their treatment choices and predict their prognosis more accurately.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"1-11"},"PeriodicalIF":1.9000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2558500","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer is the most common malignancy in women worldwide. While personalized treatment options are obstructed by the limitations of conventional biopsy follow-up, the liquid biopsy could detect the tumor's characteristics in order to reach a more targeted therapy for metastatic breast cancer patients. The aim of this article is to review the characteristics of the liquid biopsy in the follow-up of metastatic breast cancer patients. A comprehensive literature search was conducted using the PubMed literature to retrieve topic-related articles using keywords 'metastatic breast cancer,' 'liquid biopsy' and 'follow up.' A descriptive analysis was undertaken, and 29 original articles were retained. The study of blood biomarkers is being used in the monitoring and follow-up of metastatic breast cancer. It is used to determine the survival rate based on different biomarkers and monitor the response to treatment through the status of the tumor. This review describes the latest findings on breast cancer's circulating tumor cells, circulating cell-free DNA, circulating tumor DNA, proteomes, and extracellular vesicles (exosomes) in the plasma. Our literature review revealed that the liquid biopsy is capable of detecting breast cancer biomarkers in order to monitor breast cancer patients, improve their treatment choices and predict their prognosis more accurately.

查看原文本刊更多论文

液体活检：转移性乳腺癌随访的重要工具。

乳腺癌是全世界女性中最常见的恶性肿瘤。传统活检随访的局限性阻碍了个性化的治疗选择，而液体活检可以检测肿瘤的特征，从而为转移性乳腺癌患者提供更有针对性的治疗。本文的目的是回顾液体活检在转移性乳腺癌患者随访中的特点。使用PubMed文献进行全面的文献检索，检索主题词为“转移性乳腺癌”、“液体活检”和“随访”的主题相关文章。进行了描述性分析，保留了29篇原创文章。血液生物标志物的研究正被用于转移性乳腺癌的监测和随访。它用于根据不同的生物标志物确定生存率，并通过肿瘤状态监测对治疗的反应。本文综述了乳腺癌循环肿瘤细胞、循环游离DNA、循环肿瘤DNA、蛋白质组和血浆细胞外囊泡（外泌体）的最新研究进展。我们的文献综述表明，液体活检能够检测乳腺癌生物标志物，以监测乳腺癌患者，改善其治疗选择，更准确地预测其预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.